Poland· PL-100439804

Neosine Plus

A medicinal product containing inosinum pranobexum + zinci gluconas, registered in Poland by Aflofarm Farmacja Polska Sp. z o.o..

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedNeosine PlusATC—REGISTER NO.PL-100439804PACKS LISTED1CHECKEDSeptember 27, 2026

The record

At a glance

URPL (Poland)
Active substance
Inosinum pranobexum + Zinci gluconas
Manufacturer
Aflofarm Farmacja Polska Sp. z o.o.
Country
Poland (PL)
ATC code
—
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991442699

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8e8152fa-fc3a-4390-9bd5-6b3d11f42e80
GET /v1/drugs/8e8152fa-fc3a-4390-9bd5-6b3d11f42e80?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Syrop",
  "source": "urpl",
  "strength": "(250 mg + 1,5625 mg Zn2+)/5 ml",
  "packaging": "05909991442699 ¦ OTC ¦ 137307\n1 butelka 150 ml",
  "substance": "Inosinum pranobexum 250 mg/5 ml + Zinci gluconas 10.89 mg/5 ml",
  "common_name": "Inosinum pranobexum + Zinci gluconas",
  "pl_product_id": "100439804",
  "pozwolenie_nr": "26122",
  "auth_procedure": "NAR",
  "authorisation_validity": "2025-12-23"
}

See everything about inosinum pranobexum + zinci gluconas.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.